OptiNose AS

133 articles about OptiNose AS

• Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

  3/7/2023

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter and year ended December 31, 2022, and provided recent operational highlights.

• Optinose Announces Reporting Date for Fourth Quarter 2022 Financial ResultsConference Call and Webcast to be held March 7, 2023 at 8:00 a.m. Eastern Time

  2/28/2023

  Optinose today announced the Company will report financial results for the fourth quarter 2022 and corporate updates, before market open on Tuesday, March 7, 2023.

• Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion

  2/21/2023

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to request approval of XHANCE as a treatment for chronic rhinosinusitis.

• Optinose Announces CEO Transition and Business Update

  1/31/2023

  Optinose today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy Mahmoud, MD, MPH has been appointed as Chief Executive Officer and Board member.

• Optinose Appoints Paul Spence as Chief Commercial Officer

  12/15/2022

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the appointment of Paul Spence as Chief Commercial Officer.

• Optinose Announces Departure of Acting Chief Financial Officer

  12/9/2022

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company.

• Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

  11/30/2022

  Optinose today provided corporate updates and announced that CEO Peter Miller will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022.

• Optinose Announces Proposed Public Offering of Common Stock and Warrants - November 21, 2022

  11/21/2022

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering.

• Optinose Announces Pricing of Public Offering of Common Stock and Warrants

  11/21/2022

  Optinose today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock.

• Optinose Reports Third Quarter 2022 Financial Results and Operational Updates

  11/10/2022

  Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended September 30, 2022, and provided operational updates.

• Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

  11/7/2022

  Optinose announced the Company will report financial results for the third quarter 2022 and corporate updates, before market open on Thursday, November 10, 2022.

• Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

  10/21/2022

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its landmark ReOpen phase 3 clinical trial program will be presented at IDWeek 2022 in Washington, D.C. today.

• Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

  8/11/2022

  Optinose today reported financial results for the quarter ended June 30, 2022, and provided operational updates.

• Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

  7/13/2022

  XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis.

• 

  OptiNose Breathes Easy Following Data From Phase III Sinusitis Trial

  6/13/2022

  OptiNose announced positive top-line results from its Phase III ReOpen2 clinical trial testing OptiNose’s XHANCE, a fluticasone propionate nasal spray for chronic sinusitis.

• Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

  6/13/2022

  First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients.

• Optinose Announces Departure of Chief Financial Officer

  6/3/2022

  Michele Janis Appointed Acting Chief Financial Officer Anthony Krick Appointed Vice President & Chief Accounting Officer.

• Optinose Reports First Quarter 2022 Financial Results and Operational Updates

  5/12/2022

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2022, and provided operational updates.

• Optinose Announces Reporting Date for First Quarter 2022 Financial Results

  5/5/2022

  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2022 and corporate updates, before market open on Thursday, May 12, 2022.

• Optinose Announces Appointment of R. John Fletcher to the Board

  4/26/2022

  Optinose today announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director.